Publications
486 publications
- Date
- Relevance
-
Guideline for economic evaluations in healthcare (2024 version)
More often considerations are being made about the cost-effectiveness of healthcare intervention what should be reimbursed from ...
-
Advice - Reimburse voclosporin (Lupkynis®) for the treatment of rare kidney inflammation (lupus nephritis)
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse voclosporin ...
-
Advice - Adjustment of reimbursement conditions for lenacapavir (Sunlenca®)
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to adjust the conditions of ...
-
Advice - Extension of reimbursement conditions for risdiplam (Evrysdi®)
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to also reimburse risdiplam ...
-
Package advice on the lock procedure medicinal product abemaciclib (Verzenios®) for the treatment of breast cancer
The National Health Care Institute has assessed whether the medicinal product abemaciclib (Verzenios®) can be reimbursed as an ...
-
GVS advice reassessment migalastat (Galafold®) for the treatment of Fabry disease
At the request of the Minister for Health, Welfare and Sport (VWS), the National Health Care Institute assessed whether ...
-
Package advice for the lock procedure for evinacumab (Evkeeza®) for the treatment of a rare form of elevated cholesterol
The National Health Care Institute has assessed whether the medicinal product evinacumab (Evkeeza®) can be reimbursed from the ...
-
GVS advice tezepelumab (Tezspire®) for the treatment of patients 12 years and older with severe asthma
The National Health Care Institute has assessed whether tezepelumab (Tezspire®) can be included in the Medicine Reimbursement ...
-
Package advice for the lock procedure medicinal product ravulizumab (Ultomiris®) for the treatment of adult patients with myasthenia gravis
The National Health Care Institute has assessed whether the medicinal product ravulizumab (Ultomiris®) can be reimbursed from the ...
-
Advice - Extension of reimbursement conditions for lumacaftor/ivacaftor (Orkambi®)
The National Health Care Institute has investigated whether the reimbursement conditions of lumacaftor in combination with ...